Author:
Piccart M. J.,Bertelsen K.,Stuart G.,Cassidy J.,Mangioni C.,Simonsen E.,James K.,Kaye S.,Vergote I.,Blom R.,Grimshaw R.,Atkinson R.,Swenerton K.,Trope C.,Nardi M.,Kaern J.,Tumolo S.,Timmers P.,Roy J.-A.,Lhoas F.,Lidvall B.,Bacon M.,Birt A.,Andersen J.,Zee B.,Paul J.,Pecorelli S.,Baron B.,Mcguire W.
Abstract
Two independent and consecutive randomized clinical trials, conducted by the American Gynecological Oncology Group and by an European–Canadian Intergroup, have shown superiority, in clinical response rate, progression-free survival, and overall survival, of a cisplatin–paclitaxel regimen over cisplatin–cyclophosphamide given as first-line chemotherapy for women with advanced epithelial ovarian cancer. The results of these studies, published with a median follow-up of about 3 years, have been updated with a 6.5-year follow-up: In each case, an 11% absolute gain in survival favoring the paclitaxel arm is shown; this advantage remains both statistically and clinically significant and supports a role for paclitaxel in frontline chemotherapy for advanced ovarian cancer.
Subject
Obstetrics and Gynecology,Oncology
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献